Local News

• Dick Bond leaving Tyson Foods  Dick Bond, president and chief executive officer of Tyson Foods, announced he is leaving the company, effective immediately. Leland Tollett, former chairman and CEO of the company, has agreed to return to the company as President and CEO on an interim basis.
  Tyson Foods, Inc. January 05, 2009  
• Escalon buys Immunodiagnostic Systems division  Escalon Medical acquired the hematology business of Immunodiagnostic Systems Holdings for $5.9 million. Hematology, the branch of biology that looks at blood and blood-forming organs, is one of the fields for which Escalon supplies equipment to laboratories.
  Phildelphia Business Journal January 05, 2009  
• PPD enters into strategic collaboration with Merck  PPD announced it has entered into a strategic collaboration with Merck & Co. involving vaccine testing and assay development. Under the agreements, PPD purchased Merck's 130,000 square-foot vaccine testing laboratory and related equipment in Wayne, Penn.
  PPD, Inc. January 05, 2009  
• FDA Cardio Renal Advisory Committee to review Daiichi Sankyo, Lilly drug prasugrel  Daiichi Sankyo Company and Eli Lilly and Company confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009.
  Eli Lilly and Company December 31, 2008  
• Johnson & Johnson completes acquisition of Omrix Biopharmaceuticals  Johnson & Johnson announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.
  Johnson & Johnson December 30, 2008  
• Pegloticase BLA filing accepted for priority review by FDA  Savient Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients.
  Savient Pharmaceuticals, Inc. December 29, 2008  
• Celera and Abbott revise strategic alliance  Celera and Abbott announced a revision of the strategic alliance agreement between the two companies. Under a new distribution agreement, Abbott will exclusively distribute certain molecular diagnostic products manufactured by Celera.
  Celera Corporation December 29, 2008  
• Johnson & Johnson completes tender offer for Omrix Biopharmaceuticals  Johnson & Johnson announced that stockholders of Omrix Biopharmaceuticals tendered approximately 16,749,152 shares of Omrix common stock, including approximately 1,293,924 shares subject to guaranteed delivery procedures, representing approximately 97.8% of Omrix's outstanding common stock.
  Johnson & Johnson December 27, 2008  
• Synvista notified by NYSE Alternext of continued listing standards non-compliance  Synvista Therapeutics announced that on December 23, 2008, it received a notice from the staff of NYSE Alternext US indicating that the Company is not in compliance with certain NYSE Alternext continued listing standards.
  Synvista Therapeutics, Inc. December 24, 2008  
• AstraZeneca receives FDA Complete Response Letter on Seroquel XR  AstraZeneca announced the company has received a Complete Response Letter (CRL) from the FDA asking for additional information for the supplemental New Drug Application for SEROQUEL XR Extended Release Tablets for the treatment of Major Depressive Disorder (MDD) in adult patients.
  AstraZeneca December 24, 2008  

   (next 10 articles)